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Abstract
Mucin-4 (Muc4) is a large cell surface glycoprotein implicated in the protection and lubrication of 
epithelial structures. Previous studies suggest that aberrantly expressed Muc4 can influence the 
adhesiveness, proliferation, viability and invasiveness of cultured tumor cells, as well as the 
growth rate and metastatic efficiency of xenografted tumors. While it has been suggested that one 
of the major mechanisms by which Muc4 potentiates tumor progression is via its engagement of 
the ErbB2/HER2 receptor tyrosine kinase, other mechanisms exist and remain to be delineated. 
Moreover, the requirement for endogenous Muc4 for tumor growth progression has not been 
previously explored in the context of gene ablation. To assess the contribution of endogenous 
Muc4 to mammary tumor growth properties, we first created a genetically-engineered mouse line 
lacking functional Muc4 (Muc4ko), and then crossed these animals with the NDL model of ErbB2-
induced mammary tumorigenesis. We observed that Muc4ko animals are fertile and develop 
normally, and adult mice exhibit no overt tissue abnormalities. In tumor studies, we observed that 
although some markers of tumor growth such as vascularity and cyclin D1 expression are 
suppressed, primary mammary tumors from Muc4ko/NDL female mice exhibit similar latencies 
and growth rates as Muc4wt/NDL animals. However, the presence of lung metastases is markedly 
suppressed in Muc4ko/NDL mice. Interestingly, histological analysis of lung lesions from 
Muc4ko/NDL mice revealed a reduced association of disseminated cells with red and white blood 
cells. Moreover, isolated cells derived from Muc4ko/NDL tumors interact with fewer blood cells 
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when injected directly into the vasculature or diluted into blood from wild type mice. We further 
observed that blood cells more efficiently promote the viability of non-adherent Muc4wt/NDL 
cells than Muc4ko/NDL cells. Together, our observations suggest that Muc4 may facilitate 
metastasis by promoting the association of circulating tumor cells with blood cells to augment 
tumor cell survival in circulation.
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Breast cancer; HER2/ErbB2; mucin; Muc4; metastasis
Introduction
Metastasis is a fundamentally complex and inefficient process where a minority of cancer 
cells will migrate from the primary tumor, invade the vasculature, survive the harsh 
conditions of vascular transit and colonize new tissues25. Consequently, few metastases arise 
despite the potential for tumors to shed millions of cells into circulation5,10,25. Nevertheless, 
metastatic disease is the leading cause of cancer-associated mortality and is strongly 
associated with relapse following therapeutic intervention28,30,34. As such, there is an urgent 
need to understand the molecular determinants of metastasis to improve patient outcomes 
and optimize clinical disease management.
Mucin-4 (Muc4) is a large cell surface glycoprotein, composed of a heavily O-glycosylated 
extracellular alpha subunit and a membrane-anchored beta subunit that normally functions to 
lubricate and protect apical epithelial surfaces4. Several studies indicate that Muc4 augments 
cellular properties associated with the metastatic potential of carcinoma cells, and we have 
demonstrated that Muc4 protein is elevated in metastatic lesions compared to patient-
matched primary breast tumors, strongly suggesting that Muc4 confers an advantage to 
metastasizing tumor cells50.
Although the precise mechanisms by which Muc4 contributes to metastasis remain to be 
delineated, there are several plausible hypotheses. The bulky alpha subunit of Muc4 may 
promote dislodgement of tumor cells from the primary mass, enhancing invasion into the 
surrounding matrix. Indeed, Muc4 has been reported to enhance the motility, invasiveness 
and metastatic capacity of pancreatic and melanoma cancer cells6,22,23,41,46, inhibit cell-to-
cell or cell-to-matrix interactions6,20, and promote the epithelial-to-mesenchymal transition 
(EMT) upon overexpression in prostate cancer cells38,41.
Muc4 may also prepare tumor cells for hematogenous dissemination. The alpha subunit 
could serve as a physical barrier to attachment and as a sensor of biochemical changes in the 
extracellular milieu, reflected by its protective role in secretory epithelium4,47. The alpha 
subunit may likewise enable movement of tumor cells into the vasculature via glycan-
directed interactions with soluble factors and adhesion molecules. Along these lines, Muc4-
galectin complexes promoted endothelial adhesion in a pancreatic cancer model44, an 
interaction that may also facilitate extravasation at the metastatic site and inhibit suspension-
induced cell death, or anoikis17,55. Interestingly however, our group established that Muc4 
overexpression not only promotes cell survival in growth factor depleted conditions and 
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inhibits anoikis, but that these effects occur independently of the alpha subunit51. Taken 
together, these observations suggest that Muc4 upregulation may be a multifaceted 
adaptation that permits tumor cell survival during vascular transit to facilitate colonization at 
distant sites.
The most well documented role of Muc4 in the context of cancer is its capacity to modulate 
receptor tyrosine kinase signaling. In particular, Muc4 augments ErbB2/HER2 receptor-
mediated signaling in breast, melanoma, ovarian and pancreatic cancer cell 
models3,8,12,37,39. These findings are significant in that ErbB2/HER2 correlates with 
substantially lower overall survival rates, shorter disease-free intervals and increased 
incidence of metastasis18,48. However, the contribution of endogenous Muc4 to ErbB2-
mediated cancer onset and progression has not been explored. Here we employ a Muc4 
knockout mouse to demonstrate Muc4 is dispensable for the efficient growth of ErbB2-
induced primary mouse mammary tumors, but significantly enhances the occurrence of lung 
metastases. We further demonstrate that while endogenous Muc4 is sufficient to promote 
survival of tumor cells in suspension conditions, overall viability is greatly enhanced in the 
presence of platelets and immune cells. These observations firmly establish Muc4 as a 
mediator of metastasis, likely acting as a critical factor during vascular transit.
Results
Creation and characterization of Muc4tm1Unc mutant mice
Muc4-deficient mice were generated using a targeting vector that replaces 981bp of genomic 
sequence containing the starting methionine in exon 1 with a reverse-oriented floxed MC1-
neo cassette, and includes a PGK-TK cassette for negative selection (Figure 1A). Muc4tm1Unc 
founder animals were generated via homologous recombination on a mixed SV129:FvB/NJ 
background, and progeny were back-crossed at least ten generations onto the FvB/NJ strain 
prior to phenotypic analysis. Mice heterozygous for Muc4 were interbred to generate all 
genotypes designated here as wild type (Muc4wt), heterozygous (Muc4het), and knockout 
(Muc4ko). Muc4 disruption was confirmed at the transcript (Supplemental Figure 1A) and 
protein levels (Supplemental Figure 1B). No discernable effects of Muc4 disruption on 
viability, breeding or lactation were observed, and no differences in mammary gland 
architecture were noted between genotypes in adult virgin mammary glands (Supplemental 
Figure 1C).
Muc4 disruption does not delay mammary tumor onset or inhibit tumor growth
Previous studies indicate that Muc4 physically interacts with ErbB2 (ref 3) to augment its 
signaling either directly51 or indirectly via stabilization of ErbB2-ErbB3 receptor 
heterodimers12. Accordingly, Muc4 may potentiate ErbB2 pro-tumorigenic signaling to 
enhance tumorigenesis. To explore this postulate, we interbred Muc4tm1Unc FvB/NJ with a 
well-characterized mouse model in which an activated rat c-erbB2/neu allele (Neu DeLetion 
mutant, NDL) transgene is under the control of the mouse mammary tumor virus promoter 
(MMTV)16. The MMTV-NDL mouse forms highly metastatic multifocal tumors at 
approximately 20 weeks of age16. Absence of Muc4 protein in mammary tumors of 
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Muc4ko/NDL relative to Muc4wt/NDL and Muc4het/NDL female mice was confirmed by 
immunohistochemistry (Figure 1B).
Interestingly, Muc4wt/NDL tumors exhibited variable protein expression, with adjacent 
normal and stromal tissues exhibiting the most robust immunoreactivity for Muc4 beta when 
compared to the primary mass (Figure 1C). These data are consistent with our previous 
findings in human tissues, where Muc4 protein expression is down-regulated in primary 
breast tumors relative to matched normal tissue or lymph node metastases50. Muc4 also is 
not specifically elevated in tumor cells exhibiting signs of invasiveness (i.e. aligned at the 
leading edge of the tumor; see Figure 1C right panel inset, closed arrowheads), supportive of 
a relatively minor role for Muc4 during primary tumor growth and local invasion.
In support of this, we observed that Muc4wt/NDL, Muc4het/NDL and Muc4ko/NDL tumors 
emerge and grow with remarkably similar kinetics; no significant differences were apparent 
among genotypes in latency to tumor formation (Supplemental Figure 2A), the time 
necessary for tumors to reach an approximate diameter of 20mm (Figure 2A), average 
growth rates (Figure 2B), or in overall tumor burden (Figure 2C). The histopathology of 
Muc4wt/NDL and Muc4ko/NDL tumors were generally comparable, appearing as well-
differentiated, heterogeneous mammary adenocarcinomas characteristic of the NDL 
model16,45 (Figure 2D). Notably, Muc4ko/NDL lesions tended to be more cystic when 
compared to Muc4wt/NDL tumors (Supplemental Figure 2B), although this feature was not 
statistically significant (p=0.09).
The similar growth rates between genotypes could be explained by relative rates of cell 
turnover, as Muc4wt/NDL tumors had higher levels of both proliferation (Figure 2E) and 
apoptosis (Figure 2F) when compared to Muc4ko/NDL tumors. Interestingly, Muc4ko/NDL 
tumors expressed considerably lower levels of cyclin D1 (Figure 3A) and phosphorylated 
tumor cell-expressed vascular endothelial growth factor receptor 2 (pVEGF2R; Figure 3A), 
reflective of reduced angiogenic factor production. Consistent with the suppression of 
angiogenic signaling, we found a significant reduction in Muc4ko/NDL tumor vascularity as 
indicated by poor immunoreactivity for the endothelial marker, CD31 (Figure 3B).
Muc4 disruption suppresses metastasis
Our previous studies indicate that Muc4 protein is upregulated in lymph node metastatic 
lesions relative to patient-matched primary breast tumors50, raising the possibility that Muc4 
actively contributes to the metastatic process. Therefore, we analyzed lung tissue by gross 
morphology and histology (Figure 4A) and observed that, indeed, Muc4ko/NDL tumors are 
less metastatic than Muc4wt/NDL and Muc4het/NDL, despite primary lesions having been 
carried for similar amounts of time and to the same endpoint (Figure 4B). Not only did 
Muc4 expression enhance the penetrance of lesions to the lung (Figure 4B), it also 
substantially increased the total metastatic burden (Figure 4C) and extent of colonization to 
the lung parenchyma (Figure 4D).
We next examined whether Muc4 expression affects pro-metastatic factors that may permit 
the survival, migratory, or invasive capacities of tumor cells. We found that Muc4 deletion 
correlates with dramatic reductions in proteins commonly associated with EMT including 
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twist 1/2 and vimentin (Supplemental Figure 3A) are respectively substantially and modestly 
reduced in Muc4ko/NDL tumors. Lung metastases exhibited similar trends, where vimentin 
is elevated in Muc4wt/NDL lesions compared to Muc4ko/NDL (Supplemental Figure 3B). 
While we anticipated that reductions in EMT-associated proteins would attenuate migration, 
we observed no differences in the abilities of ex vivo dissociated tumor cells to migrate in a 
transwell assay (Supplemental Figure 3C). Taken together, these data suggest that Muc4 
dramatically modifies tumor protein expression but that these alterations are not sufficient to 
elevate migratory capacity.
Muc4 may facilitate metastasis via physical interactions with blood cells
Disrupted VEGFR signaling may reduce both the abundance and permeability of the tumor-
associated vascular bed35 and therefore the relative efficiency of NDL cells to access 
essential networks for metastasis. Accordingly, we evaluated whether Muc4 benefited tumor 
cells even when given equal access to vasculature. Indeed, Muc4wt/NDL cells instilled 
directly to the lateral tail vein generated more metastatic lesions to the lung compared to 
Muc4ko/NDL cells (Figures 5A and 5B). When lesions were stratified by type (colonized, 
emboli), we found a significant difference in the capacity of Muc4wt/NDL cells to colonize 
the lung parenchyma (Figures 5C and 5D). It is likely Muc4 conveys a significant survival 
advantage to tumor cells, reflected in the enhanced viability of Muc4wt/NDL cells when 
subjected to an anoikis assay in vitro (Supplemental Figure 4A). Finally, we observed that 
Muc4 may be specifically upregulated during vascular transit, as its expression appeared to 
be strongest in tumor cells found either within or in close proximity to vascular lumens and 
reduced in established lung lesions (Figure 5E).
Disseminated tumor cells are known to travel as complex aggregates, consisting of clusters 
of cancer cells, platelets and other blood cells. These microthrombi are thought to critically 
improve tumor-cell survival and extravasation by promoting long-term adhesion and arrest 
within microvasculature, while shielding tumor cells from the shear stress imposed during 
transit in circulation25. To explore whether some of the pro-metastatic effects of Muc4 could 
arise from tumor cell interactions with platelets and other blood cell components, we first 
histologically assessed the association of tumor cells with blood cells in lung lesions. By 
standard hematoxylin and eosin staining, we noted a substantial increase in the abundance of 
platelets and immune cells within Muc4wt/NDL relative to Muc4ko/NDL emboli (H&E, 
Figure 6A; arrowheads), further verified by specific staining for macrophages (F4/80) and 
platelets (CD41, Figure 6A). A majority of the cells were immunoreactive for CD41, 
suggesting an abundance of platelets and/or hematopoietic progenitors31 although it is 
unclear whether they infiltrated the lesion locally at the lung or if they were a component of 
the original circulating microthrombi. Nevertheless, Muc4wt/NDL lesions were more 
proliferative when compared to Muc4ko/NDL lesions (phosoho-histone H3, Figure 6A), a 
feature which may partially account for differences in colonizing ability.
To explore whether the presence of Muc4 enhances the interaction of tumor and blood cells, 
we developed an in vitro suspension assay in which blood cells were admixed with either 
Muc4wt/NDL or Muc4ko/NDL tumor cells. After 1.5hrs and 24hrs, we noted a significant 
increase in the number of blood cells that were closely associated with individual 
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Muc4wt/NDL tumor cells or tumor cell aggregates (Figure 6B and Supplemental Movies 1 
and 2; P <0.05). Importantly, we found similar interactions to occur in vivo, where tail vein 
injected Muc4wt/NDL cells were more likely to be found with large clusters of blood cells 
(Figure 6C).
It is likely the physical interaction of Muc4 with blood cells is requisite for survival, 
suggested by enhanced survival (Figure 6D and Supplemental Figure 4B) and sphere 
forming capacity (Supplemental Figure 4C) only when Muc4wt/NDL cells were directly co-
cultured with blood cells. These effects relied solely on the status of Muc4 in the tumor cell, 
as blood cells derived from Muc4ko and Muc4wt mice were equally capable of improving the 
viability of suspension cultured Muc4wt/NDL cells (Figure 6D).
Discussion
In the context of cancer, Muc4 has been shown to initiate signaling cascades through 
interactions with members of the ErbB family of receptor tyrosine kinases. In particular, the 
association of Muc4 with ErbB2/HER2 enforces receptor complex stability at the plasma 
membrane and potentiates tyrosine phosphorylation of ErbB2 to augment cellular 
differentiation, proliferation and survival3,4,12. We now provide appreciable insight into 
Muc4 biology by establishing its primary role in the malignant progression of ErbB2-
overexpressing mammary carcinomas. While we found that Muc4 is dispensable for primary 
tumor growth, it significantly augments the efficiency of metastasis, reflected by an 
increased occurrence, burden and colonization of secondary lesions in the lung. We provide 
further mechanistic insight that Muc4 engages a complex survival strategy that is likely to 
encompass both intrinsic signaling and intercellular interactions during the hematogenous 
dissemination of tumor cells.
These findings are significant, as vascular transit represents a particularly vulnerable stage of 
metastasis, where tumor cells must remain viable under suspension conditions, withstand 
significant shear stresses and evade immune surveillance25. Disseminated tumor cells are 
thought to interact with immune cells and platelets13,25, which may potentiate their demise15 
or promote their survival2,14,40. For example, a recent study demonstrated metastatic 
colonization of breast cancer cells to the lung was aided by the formation of extracellular 
nets by neutrophils, ostensibly facilitating expansion of lodged tumor cells36. Recruitment of 
neutrophils and other leukocytes may be accomplished by the formation of platelet-tumor 
cell aggregates, which would be more likely to become entrapped in microvessels than 
individual cancer cells25. In turn, clot formation may enhance survival, early niche creation 
and extravasation via recruitment of macrophages to the site of arrest14.
The association of platelets with disseminated cancer cells is so pervasive that platelets or 
platelet mimics are currently being engineered as anti-cancer therapeutics to deliver 
cytotoxic agents to tumor cells19,26,27. On the other hand, inhibition of platelet 
aggregation11,13 or immune cell function14,36,40 is sufficient to impede metastasis. Our 
observations strongly suggest that Muc4 is an essential component of such blood cell-tumor 
cell interactions, reflected by the association of platelets and immune cells with both 
circulating and lodged Muc4wt/NDL cells. Further to this, our in vitro studies suggest this 
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interaction enhances the survival of Muc4-expressing cells under suspension conditions, as 
might be expected during vascular transit.
These data impart additional complexity to our understanding of Muc4. Previous reports 
imply that Muc4 protects circulating tumor cells from immune destruction21 as a result of 
the ability of its bulky glycosylated extracellular region to mask surface epitopes and inhibit 
immune recognition7. While our data do not directly refute or support this model, we found 
no decrease in the survival in Muc4ko/NDL cells when co-cultured with blood cells, 
suggesting that viability is not based on immune destruction per se. It is worth noting a 
recent study in which Muc4 was enhanced in both chronic and acute models of 
inflammation29, lending further credence to the postulate that Muc4 acts as a critical survival 
factor during periods of heightened immune response.
Beyond demonstrating a pro-survival function of Muc4, we provide evidence that it is 
required for robust tumor angiogenesis. Along these lines, Muc4ko/NDL tumors exhibited 
reduced phosphorylation of VEGFR2R and blood vessel formation, suggesting that 
differences in the rate of metastasis may partially depend on the relative abundance of 
vessels in which to invade. Previous reports indicate that Muc4 is expressed by differentiated 
endothelial cells, is associated with the luminal surfaces of blood vessels50,53,54 and when 
knocked down attenuates VEGF expression and angiogenesis56. Whether Muc4 presence in 
endothelial or epithelial cells is essential or permissive for blood vessel formation has yet to 
be established. However, its specific upregulation in endothelium during intermediate stages 
of wound-induced angiogenesis54, and its association with epithelium-derived regulators 
such as ErbB2 (refs 24,32), β-catenin and VEGF56, point to possible roles. While our 
current model precludes extensive investigation of the differential requirements for epithelial 
and endothelial Muc4 in angiogenesis, future cross-transplantation studies in which Muc4 
replete epithelium is transplanted into knockout stromal tissue and vice versa may yield 
valuable insight.
We also found expression of proteins implicated in EMT (twist and vimentin) to be 
markedly attenuated in the absence of Muc4. While we were unable to demonstrate a 
significant difference in migratory capacity with a loss of Muc4, the dramatic reduction in 
both metastasis and in the expression of key metastatic drivers suggest it as a potential 
therapeutic target, especially in the context of HER2-positive breast carcinomas.
Materials and Methods
Generation of Muc4tm1Unc mice
The University of North Carolina (UNC) Animal Models Core (Chapel Hill, NC, USA) 
generated Muc4-deficient mice via homologous recombination in mouse embryonic stem 
cells. Briefly, a 129SvEv BAC mouse genomic library was screened for Muc4 genomic 
sequences containing exon 1 using two Muc4 cloned sequences (a 430bp fragment from 
6824-7254 and a 347 bp fragment from 10716-11063 of sequence NM_080457). Short and 
long arm homologous fragments were cloned from the Muc4 genomic BAC into targeting 
vector pOSdupdel6142-SA vector to generate the targeting vector pOSdupdel6142-Muc4 
which was electroporated into 129SvEv embryonic stem (ES) cells. ES cell clones with the 
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targeted recombination event were selected with Geneticin and ganciclovir, screened by 
PCR and confirmed by Southern blot (not shown) prior to injection into FvB/NJ blastocysts 
to generate chimeric founders. Founder males from identified ES cell lines were crossed to 
FvB/NJ female mice to yield Muc4tm1Unc mice heterozygous for the targeted allele, and 
these were then crossed to initiate Muc4tm1Unc lines. Nomenclature was developed in accord 
with the International Committee on Standardized Genetic Nomenclature for Mice as 
implemented by the Mouse Genomic Nomenclature Committee. Loss of Muc4 protein was 
confirmed with a Muc4 mouse monoclonal antibody to the beta subunit as described50.
Generation of Muc4/NDL mice
All experimental protocols were approved by the IACUC of the University of California, 
Davis, USA. The NDL mouse model has previously been described45. Muc4het females were 
crossed with NDL males to generate Muc4wt/NDL, Muc4het/NDL and Muc4ko/NDL 
genotypes. Genotypes were confirmed using polymerase chain reaction (PCR) by 
commercial vendor (Muc4, Transnetyx, Cordova, TN USA) or in house (NDL) using 
primers for Muc4 (Fwd-AGCTAAAGAATGTGGCCATAAAGGA; Rvs-
CGTTCCCACCATCCTCCAAAA), neomycin (Fwd-GGGCGCCCGGTTCTT; Rvs-
CCTCGTCCTGCAGTTCATTCA) and NDL (Fwd-TTC CGG AAC CCA CAT CAG; Rvs- 
GTT TCC TGC AGC AGC CTA).
Quantitative PCR
Tissue was homogenized in Trizol reagent (Thermo Fisher Scientific; Waltham, MA, USA) 
by Dounce homogenizer per manufacturer’s guidelines. Total RNA was purified using an 
RNA purification kit (Thermo, Cat# 12183025) and complementary DNA prepared as 
described52. Quantitative PCR was carried out as described49 using probe sets specific for 
Muc4 (mm0046688_m1) with glyceraldehyde-3-phosphate dehydrogenase (GAPDH, 
435293E) used for normalization.
Tumor monitoring and analysis
Mammary tumors were palpated twice weekly in female NDL mice commencing at 12 
weeks of age by a single investigator partially blinded to genotypes. As tumors form in 
multiple mammary glands in the NDL model45, the growth rates of all tumors were recorded 
by caliper measurements. The leading tumor was allowed to reach a maximum diameter of 
20mm, at which time the mice were euthanized by CO2 asphyxiation, lungs collected and 
fixed for whole mount analysis and tumors bisected and randomly allocated to either fixation 
in 10% neutral buffered formalin and paraffin embedding or further dissociation for in vitro 
studies. Animals with illness arising independent of their tumors that required sacrifice prior 
to the tumor reaching predetermined criteria were excluded from analyses.
Histology and Immunohistochemistry
Histological analysis was performed for a randomly selected subset of the most advanced 
tumors (n≥7). H&E stained sections were prepared from Muc4wt/NDL and Muc4ko/NDL 
tumors using previously described methods42 with analysis of tumor features carried out 
blinded by a licensed pathologist. Immunohistochemistry was performed essentially as 
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described52 with the substitution of 10% normal goat serum for protein blocking, Bloxall for 
blocking endogenous peroxidase (Vector Laboratories, Burlingame, CA USA), DAB as the 
chromogen (Vector) and tris-buffered saline with 0.1% tween as the buffer for 
phosphorylated antibodies. Antibodies used for immunohistochemistry are listed in 
Supplemental Table 1. Tumor sections were prepared as an array (n=3 to 4 tumors of the 
same genotype on a single slide) or as individual tumors from a single source. Where used, 
staining intensities were scored with the scale: 0=negative, 1=weak, 2=moderate and 
3=strong with the accuracy of scoring confirmed by a blinded observer. An internal negative 
control (no primary antibody) was included with each trial.
Lung Analysis
Lungs were inflated with phosphate buffered saline (PBS), fixed in formalin for 24hrs and 
stained in carmine alum as described52. Gross lesions were imaged under a dissecting 
microscope (Zeiss Stemi 2000-C; Axiocam ERc/5s) and further dissected for confirmation 
by histology. Microlesions were evaluated separately by histology of 4-step serial sections 
(5μm, n=3) taken at 40-50μm intervals.
Tail Vein Injections
Pooled primary Muc4wt/NDL or Muc4ko/NDL cells (n=4 per genotype; 5 × 105 in 200uL 
PBS) were instilled under isoflurane anesthesia to the lateral tail vein of 9-week old FvB/NJ 
female mice (Jackson Laboratory, Bar Harbor, ME). Blood and tissues (lung, liver, spleen, 
uterus, brain, kidney, digestive tract) were collected 3d (n=4/line) and 28d (n=6/line) later 
for circulating tumor cell assays and analysis of metastasis, respectively. Mice were 
randomly assigned to both treatments and time of sacrifice and were caged as mixed cohorts.
Cell Culture
Cells were maintained in DMEM + 10% fetal bovine serum (FBS, Axenia Biologix, Dixon, 
CA USA) and penicillin/streptomycin (Gibco, Waltham, MA USA) at 37°C under 10% CO2 
and were were routinely passaged using 0.05% typsin-EDTA (Gibco). Primary NDL tumor 
cells were dissociated by enzymatic and mechanical methods essentially as described for 
normal mammary tissue42 from Muc4wt/NDL (n=4) and Muc4ko/NDL (n=4) tumors. Tumor 
cells were harvested from the most advanced tumor and used within four passages to ensure 
equal comparison. The expression of Muc4 was retained over this duration, as confirmed by 
immunocytochemistry (data not shown).
Anoikis assay
Primary NDL cells were plated at a density of 3 × 103 cells/mL in basal media in ultra-low 
adherence culture plates (Corning, Corning, NY USA) for 24hrs and viability in suspension 
conditions determined by trypan blue exclusion assay as described43.
Blood cell co-culture suspension assays
Blood was harvested from 8-12 week-old Muc4wt (n=6) or Muc4ko mice (n=6) via cardiac 
puncture, added to 3.8% sodium citrate (9:1) to prevent clot formation and centrifuged at 
~130 × g for 10 min at room temperature. The upper fraction containing plasma, immune 
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cells and platelets (platelet-rich plasma) was re-centrifuged at ~300 × g to separate the 
cellular and plasma fractions. Blood cells were re-suspended in Iscove’s Modified 
Dulbecco’s Media (IMDM, Gibco)9 with 10% FBS (blood cell fraction; BC), combined with 
Muc4wt/NDL or Muc4ko/NDL cells at a ratio of 50 to 100:1, and cultured in ultra-low 
adherence conditions for 24hrs. Controls included IMDM + 10% FBS or IMDM + 10% 
FBS/cell-free plasma (CFP).
Under ultra-low adherence conditions, NDL cells form small spheroids that are 
distinguishable from single white or red blood cells. For viability assays, tumor cells were 
pre-incubated with MitoFluor green (Molecular Probes, Waltham, MA USA) for 30 min 
prior to co-culture to ensure their later discrimination from blood cells. MitoFluor green 
label retention was verified to extend beyond 36hrs in NDL cells (data not shown) and was 
chosen for its capacity to effectively label all cells without adversely affecting viability. 
Within 30 min prior to concluding co-culture experiments, the entire culture was incubated 
with the vital nuclear stain Hoechst 33342 (Promokine, Heidelberg, Germany; ex. 350 
nm/em. 461nm) to detected nucleated immune and tumor cells, washed gently in PBS to 
remove unbound dye and stained with ethidium homodimer II (Promokine; ex. 528nm/em. 
617nm) to identify dead/dying cells with poor membrane integrity. Non-nucleated platelets 
remained unstained. Spheres were pipetted onto microscope slides (Thermo), cover slipped 
and immediately imaged with an Olympus BX51 (Center Valley, PA USA) fluorescence 
microscope fitted with a Nuance FX CRI camera.
For association assays, pooled NDL cells (n=4/line) and blood cells were monitored and 
imaged at 1.5hrs and 24hrs on an Olympus IX81 microscope with Olympus cellSens Entry 
software. Interactions were considered to include the residence of any blood cell within 
close proximity (≤5μm) to a tumor cell. Time-lapse images of a single field were captured at 
1s intervals for 30-40s.
Circulating tumor cell assay
Whole blood (~1mL) was harvested as described above from mice injected at the lateral tail 
vein 3d prior with pooled NDL cells. Blood was immediately fixed in 4% paraformaldehyde 
for 2hrs, centrifuged (~300 × g) and washed in PBS. Nuclei were stained with DAPI for 1hr 
at room temperature, plated on a glass microscope slide in a small volume of PBS and 
evaluated by fluorescence (tumor cells) and bright field (blood cells) microscopy.
Transwell migration assay
Primary NDL cells were subjected to the transwell migration assay as described49, with 
some modifications. Cells were plated directly onto the transwell in serum starve media 
(0.1% FBS) at a density of 2.5 × 104 cells/mL and migration was permitted for 16hrs. 
Migrated cells were fixed and stained with Diff-Quick staining solution (Dade Behring, 
Deerfield, IL, USA) prior to imaging with an Olympus IX81.
Statistics, data and image analysis
Values are expressed as means ± standard deviations. For in vitro experiments, data 
represent at least three biological replicates preformed with a minimum of duplicate 
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technical replicates. Data for in vivo studies reflect means of 4-6 (tail vein assays) or ≥12 
mice (genetic studies) per line. Cohorts were based on two-sided power calculations 
(P=0.05, 80% power) to detect differences in tumor growth/metastasis and are consistent 
with previous studies1,33. Statistical significance was established using independent two-
sided Student’s t-test (with variance assumptions based on F-tests), Mann-Whitney U test 
(non-linear values- IHC, tumor burden and lung metastases) or log-rank test (survival 
curves) with P-values less than 0.05 considered statistically significant. Data were analyzed 
with Microsoft Excel or R-statistical platform. Images were compiled in Adobe Photoshop 
with brightness, contrast and white balance modified only for clarity in print. Cell counting 
was performed using image J (NIH; http://rsb.info.nih.gov/ij/).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Muc4 is effectively depleted by targeted knockdown
(A) The strategy employed to functionally delete the murine Muc4 gene is depicted. 
Homologous recombination of the targeting vector with genomic Muc4 replaces exon 1 with 
a neomycin resistance cassette (Neo) transcribed in the direction indicated by the arrow; 
thymidine kinase (TK) in the targeting vector was included for negative selection. Insertion 
of Neo introduced a Pst1 restriction site that was used to confirm knockout in ES cells by 
Southern blot (not shown) using the probe indicated by the dotted box. The schematic is not 
shown to scale. (B) Functional deletion of Muc4 in NDL mammary tumor tissue was 
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confirmed by immunohistochemistry using an antibody that detects the beta subunit of 
Muc4. Representative images were selected from at least three biological replicates. (C) 
Representative images selected from at least three biological replicates highlighting the 
variability in the level of Muc4 expression between the primary mass and its adjacent 
tissues. Muc4 protein expression was detected as described above. Normal adjacent 
mammary ducts (left panel) and stromal tissues (right panel) exhibit robust expression of 
Muc4. Boxed regions have been expanded to show detail (insets). Muc4 positivity was also 
noted in blood vessels (right inset, asterisk), as previously described50. Tumors have 
comparably weaker expression of Muc4, even at the invasive edge (right panel inset, open 
arrowheads). Scale bars in all images = 250μm.
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Figure 2. Muc4 deletion modestly alters primary mammary tumor histology but does not affect 
mammary tumor latency or growth rate in the NDL model
(A-C) Survival curves and box plots depicting Muc4/NDL tumor growth characteristics. 
Latency to tumor formation (A), tumor growth rate (B), and the overall tumor burden 
(number of glands with tumors) (C), were not significantly different among genotypes 
(Muc4wt/NDL [n=13], Muc4het/NDL [n=14] and Muc4ko/NDL [n=12]). Data are presented 
as means ± SD and significance determined by log-rank test (A) or 2-sided Students-t test 
(B-C). (D) Representative H&E images are depicted of formalin fixed, paraffin embedded 
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sections from Muc4wt/NDL and Muc4ko/NDL primary tumors. Tumors from both genotypes 
develop as heterogeneous mammary adenocarcinomas displaying nests of tumor epithelium 
(asterisks) and abundant lumina (closed arrowheads) that are structurally distinct from 
endothelial lined blood vessels (open arrowheads). (E) Representative images Muc4wt/NDL 
and Muc4ko/NDL primary tumor tissues following immunodetection of the proliferation 
marker phospho-histone H3. Quantification of at least six biological replicates revealed a 
significant reduction in the number of proliferating cells with loss of Muc4 (**, P<0.01; t-
test). The percent of pH3 positive cells/total cells is plotted. Examples of positive nuclei are 
denoted by closed arrowheads. (F) Immunodetection of cleaved caspase-3 suggests a modest 
yet insignificant reduction in the rate of apoptosis with Muc4 loss (P=0.05; t-test). Data are 
averages from at least five biological replicates and expressed as the percent of total cells 
positive for cleaved caspase-3 ± SD, where examples of positive cells are indicated with 
closed arrowheads. Scale bars in all images = 250μm.
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Figure 3. Muc4 deletion has potent effects on protein expression and vascularity
(A) Muc4wt/NDL (n=7) and Muc4ko/NDL (n=8) tumors were stained for cyclin D1, and 
scored on a scale of 0-3 (0=negative, 3=strong; not shown). Mann Whitney U test revealed 
significantly lower cyclin D1 expression in Muc4ko/NDL tumors (P < 0.01). Similarly, the 
expression of phosphorylated VEGF2R (pVEGF2R) is increased in Muc4wt/NDL tumors 
relative to Muc4ko/NDL tumors. Total VEGF2R was visually similar between the two 
genotypes. (B) Primary tumors were stained for CD31 to calculate blood vessel density 
(percent of CD31 positive vessels/area). Student’s t-test revealed Muc4wt/NDL tumors 
exhibit significantly elevated vascular content compared to Muc4ko/NDL tumors (*, 
P<0.05). Images are representative of at least seven biological replicates. Scale bars in all 
images = 250μm.
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Figure 4. Muc4 deletion markedly suppresses metastasis to the lung
(A) Carmine alum stained lung tissue from Muc4wt/NDL, Muc4het/NDL and Muc4ko/NDL 
mice were evaluated for the occurrence of gross lesions (open arrowheads) under a 
dissecting microscope. Lesions were subsequently isolated, embedded in paraffin and 
sectioned for further evaluation by routine histology. Metastatic lesions were classified as 
either emboli (contained within vascular walls; open arrowheads) or colonized (within lung 
parenchyma; closed arrowheads). Representative H&E stained sections are depicted. Scale 
bar = 1mm. (B) Lung tissues from multiple mice were evaluated for the occurrence of gross 
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and microlesions (n=9 Muc4wt/NDL; n=8 Muc4het/NDL; n=9 Muc4ko/NDL). The numbers 
of mice bearing metastatic lesions is compared to the corresponding primary tumor latencies 
and growth rates for each genotype. (C) The numbers of gross metastatic lesions and 
involved lung lobes per mouse (mean ± SD) are depicted for the three genotypes. 
Significance was determined by Mann Whitney test with continuity correction. (D) The 
percent (mean ± SD) colonized lesions is plotted for each genotype. Student’s t-test revealed 
a significant difference in the percent of colonizing lesions. *, P < 0.05; **, P < 0.01 for all 
panels.
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Figure 5. Muc4 deletion impairs the metastatic capacity of tail vein injected NDL cells
Pooled (n=4 independent biological sources per line) primary Muc4wt/NDL and 
Muc4ko/NDL tumor cells were instilled into the lateral tail vein of FVB wt mice (n=6). 
Tissues (lungs, digestive tract, liver, spleen, uterus, brain) were collected 28d later, fixed in 
4% paraformaldehyde and evaluated for the appearance of gross metastasis. Only lungs were 
found to contain gross lesions, more readily visible by carmine alum stain (A). Scale bar = 
1mm. (B-D). H&E stained sections were used to quantify the occurrence of metastatic 
lesions. The total number of metastases (B) and the frequency of colonized lesions (C) 
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formed in the lungs of mice injected with Muc4wt/NDL cells was significantly increased 
compared to those receiving Muc4ko/NDL cells. There was a modest reduction in the 
frequency of emboli formed by Muc4ko/NDL cells (P = 0.086). Representative H&E stained 
sections are presented in (D). Closed grey arrowhead, emboli; closed black arrowhead, 
colonized lesion. Scale bar = 1mm. (E) The level of Muc4 expression within a colonized 
lesion is heterogeneous, where it is strong both within (open arrowhead) and around the 
vascular lumen (closed black arrowhead) but is decreased in tumor cells found further away 
from this region (closed white arrowhead). Tissue was stained with an antibody to Muc4 
beta, as described in Figures 1B and 1C. Scale bar = 150μm.
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Figure 6. Deletion of Muc4 suppresses the association of tumor cells with red and white blood 
cells in vitro and in vivo
(A) Representative H&E stained lung lesions from Muc4wt/NDL and Muc4ko/NDL mice, 
illustrating the elevated abundance of blood cells (closed arrowheads) in Muc4wt/NDL 
emboli. Immunodetection of proteins specific to macrophages (F4/80) and platelets, 
megakaryocytes and hematopoietic progenitors (CD41/Integrin alpha 2b) indicated the 
majority of associated blood cells to be CD41 positive. Phospho-histone H3 (pH3) staining 
revealed Muc4wt/NDL lung lesions were more proliferative than Muc4ko/NDL lesions. Scale 
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bar in all images = 100μm. Images are representative of at least 6 biological replicates. (B) 
Quantification of tumor cell-blood cell associations (proximity of < 5μm) using bright field 
microscopy of live cells revealed a reduced number of associated blood cells at either 1.5hrs 
or 24hrs after the initiation of co-culture conditions. Pooled NDL cells (n=4 biological 
sources per line) were used for these experiments and data are presented as averages of three 
independent experiments ± SD. Scale bar = 50μm. *, P < 0.05. (C) Similar associations were 
noted for Muc4wt/NDL cells in vivo, where the abundance of closely associated blood cells 
appears visibly enhanced by the presence of Muc4. Pooled Muc4wt/NDL or Muc4ko/NDL 
cells (n=4 biological sources per line) were instilled into the lateral tail vein of female mice 
(n=4 per line) and whole blood was collected by cardiac puncture 3d later and immediately 
fixed in 4% paraformaldehyde. Nuclei were stained with DAPI and individual cell clusters 
imaged by fluorescence and bright field microscopy. Scale bar = 200μm. (D) Muc4-
mediated tumor cell association with blood cells promotes tumor cell viability in suspension. 
Primary Muc4wt/NDL and Muc4ko/NDL tumor cells (n=3 per line) were labeled with 
MitoFluor green, and cultured in suspension for 24hrs after admixing with basal media, 
freshly harvested blood cells in basal media, or cell free-plasma (CFP) in basal media 
harvested from Muc4wt or Muc4ko mice. Hoechst 33342 was used as a nuclear stain to 
discern platelets from immune and tumor cells, and MitoFluor green was used to distinguish 
tumor cells from immune cells. Percent cytotoxicity (mean ± SD) was determined within 
tumor sphere aggregates by positive staining for ethidium homodimer. Student’s t-test 
revealed blood cells significantly suppress the death of Muc4wt/NDL but not Muc4ko/NDL 
cells. The origin of the blood cells (Muc4wt or Muc4ko) did not affect outcomes. Images are 
presented as final merged composites. Unmerged images may be found in Supplemental 
Figure 4B. Scale bar = 200μm. *, P < 0.05; ***, P < 0.001.
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